The Swiss pharma has extended its tender offer for its $4.8 billion buy of the gene therapy pioneer after failing to secure a majority of shares by a deadline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,